SCHEMBL1747073

SCHEMBL1747073

COC(=O)CCc1cc(I)c2oc(-c3ccc(OC)cc3)cc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.44
MAPT P10636 6/20 0.41
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 3/20 0.41
PKM P14618 2/20 0.41
VDR P11473 1/20 0.41
PPARD Q03181 1/20 0.41
HSD17B1 P14061 1/20 0.40
HSD17B2 P37059 1/20 0.40
EGFR P00533 1/20 0.40
HPGD P15428 2/20 0.40
GAA P10253 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
F2RL1 P55085 1/20 0.39
MAOB P27338 1/20 0.39
NTRK1 P04629 1/20 0.39
NTRK2 Q16620 1/20 0.39
CYP3A4 P08684 2/20 0.39
CYP1A2 P05177 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1744659 0.81 MAOA (0.62) MAOAMAPTALDH1A1KDM4EHPGD
SCHEMBL18224269 0.79 FASN (0.49) MAPTALDH1A1KDM4EVDRMEN1
SCHEMBL18224254 0.76 FASN (0.52) MAPTALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL18224256 0.76 VDR (0.50) MAOAMAPTVDRPPARDHSD17B1
SCHEMBL18274882 0.75 FFAR1 (0.51) MAPTPPARDTP53PPARG
SCHEMBL18224258 0.75 TERT (0.47) MAPTALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL14485257 0.74 PCNA (0.61) MAPTALDH1A1F2RL1MEN1KMT2A
SCHEMBL2277479 0.72 F2RL1 (0.67) MAPTALDH1A1SMN1; SMN2F2RL1MAOB
SCHEMBL18224405 0.72 FASN (0.47) MAPTALDH1A1VDRPPARDHPGD
SCHEMBL1445627 0.70 F2RL1 (0.73) MAPTALDH1A1SMN1; SMN2F2RL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR MAOA 4245/4885MAPT 4718/4885ALDH1A1 4258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.